Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results for the First Half 2013
8/22/2013 6:33:32 AM
Get the latest biotech news where you want it. Sign up for the free GenePool
Hørsholm, Denmark, 21 August, 2013
Veloxis Pharmaceuticals announces financial results for the first half 2013
-- LCP-Tacro(TM) has successfully demonstrated non-inferiority compared to
tacrolimus (Prograf(R); Astellas Pharma) in its Phase III clinical trial,
Study 3002. The Phase III randomized, double-blind and double-dummy study
in 543 de novo kidney transplant recipients, with Prograf(R) as the
comparator, met its primary efficacy and primary safety endpoints.
Help employers find you! Check out all the jobs and post your resume.